Recent Publications

• Novel treatment for PXE: Recombinant ENPP1 enzyme therapy.Jacobs IJ, Obiri-Yeboah D, Stabach PR, Braddock DT, Li Q. Mol Ther. 2024 Nov 6; 2024 Sep 27. PMID: 39342427.
• Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia.Kato H, Ishihara Y, Ohata Y, Irie K, Watanabe S, Kimura S, Hoshino Y, Hidaka N, Kinoshita Y, Taniguchi Y, Kobayashi H, Braddock DT, Kubota T, Ozono K, Nangaku M, Makita N, Ito N. J Endocr Soc. 2024 Oct 29; 2024 Oct 22. PMID: 39498416.
• Quantitative correlation of ENPP1 pathogenic variants with disease phenotype.Ansh AJ, Stabach PR, Ciccone C, Cao W, De La Cruz EM, Sabbagh Y, Carpenter TO, Ferreira CR, Braddock DT. Bone. 2024 Sep; 2024 May 26. PMID: 38806089.
• A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models.Stabach PR, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez SG, Petri M, Goldman DW, Lester ER, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira JP, Yarema KJ, Koumpouras F, Andrade F, Braddock DT. JCI Insight. 2024 Jun 18; 2024 Jun 18. PMID: 38888971.
• ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency.Ferreira CR, Carpenter TO, Braddock DT. Annu Rev Pathol. 2024 Jan 24; 2023 Oct 23. PMID: 37871131.
• Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments.Kato H, Braddock DT, Ito N. Curr Osteoporos Rep. 2023 Oct; 2023 Aug 2. PMID: 37530996.
• Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.Murtada SI, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra AB, Li DS, Braddock DT, Tellides G, Gordon LB, Humphrey JD. Elife. 2023 Mar 17; 2023 Mar 17. PMID: 36930696.
• Catalysis-Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass.Zimmerman K, Liu X, von Kroge S, Stabach P, Lester ER, Chu EY, Srivastava S, Somerman MJ, Tommasini SM, Busse B, Schinke T, Carpenter TO, Oheim R, Braddock DT. J Bone Miner Res. 2022 Sep; 2022 Jul 29. PMID: 35773783.
• Characterization of hearing-impairment in Generalized Arterial Calcification of Infancy (GACI).Theng EH, Brewer CC, Oheim R, Zalewski CK, King KA, Delsmann MM, Rolvien T, Gafni RI, Braddock DT, Jeffrey Kim H, Ferreira CR. Orphanet J Rare Dis. 2022 Jul 19; 2022 Jul 19. PMID: 35854274.
• Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis.Kato H, Ansh AJ, Lester ER, Kinoshita Y, Hidaka N, Hoshino Y, Koga M, Taniguchi Y, Uchida T, Yamaguchi H, Niida Y, Nakazato M, Nangaku M, Makita N, Takamura T, Saito T, Braddock DT, Ito N. J Bone Miner Res. 2022 Jun; 2022 Apr 11. PMID: 35340077.
• Strategies for Glycoengineering Therapeutic Proteins.Dammen-Brower K, Epler P, Zhu S, Bernstein ZJ, Stabach PR, Braddock DT, Spangler JB, Yarema KJ. Front Chem. 2022; 2022 Apr 13. PMID: 35494652.
• Musculoskeletal Comorbidities and Quality of Life in ENPP1-Deficient Adults and the Response of Enthesopathy to Enzyme Replacement Therapy in Murine Models.Ferreira CR, Ansh AJ, Nester C, O'Brien C, Stabach PR, Murtada SI, Lester ER, Khursigara G, Molloy L, Carpenter TO, Braddock DT. J Bone Miner Res. 2022 Mar; 2021 Dec 26. PMID: 34882836.
• Direct targeting of amplified gene loci for proapoptotic anticancer therapy.Kaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiak A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA. Nat Biotechnol. 2022 Mar; 2021 Oct 28. PMID: 34711990.
• Cardiomyocytes disrupt pyrimidine biosynthesis in nonmyocytes to regulate heart repair.Li S, Yokota T, Wang P, Ten Hoeve J, Ma F, Le TM, Abt ER, Zhou Y, Wu R, Nanthavongdouangsy M, Rodriguez A, Wang Y, Lin YJ, Muranaka H, Sharpley M, Braddock DT, MacRae VE, Banerjee U, Chiou PY, Seldin M, Huang D, Teitell M, Gertsman I, Jung M, Bensinger SJ, Damoiseaux R, Faull K, Pellegrini M, Lusis AJ, Graeber TG, Radu CG, Deb A. J Clin Invest. 2022 Jan 18. PMID: 34813507.
• Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice.Ferreira CR, Kavanagh D, Oheim R, Zimmerman K, Stürznickel J, Li X, Stabach P, Rettig RL, Calderone L, MacKichan C, Wang A, Hutchinson HA, Nelson T, Tommasini SM, von Kroge S, Fiedler IA, Lester ER, Moeckel GW, Busse B, Schinke T, Carpenter TO, Levine MA, Horowitz MC, Braddock DT. J Bone Miner Res. 2021 May; 2021 Feb 18. PMID: 33465815.
• Improving the Pharmacodynamics and In Vivo Activity of ENPP1-Fc Through Protein and Glycosylation Engineering.Stabach PR, Zimmerman K, Adame A, Kavanagh D, Saeui CT, Agatemor C, Gray S, Cao W, De La Cruz EM, Yarema KJ, Braddock DT. Clin Transl Sci. 2021 Jan; 2020 Oct 20. PMID: 33064927.
• Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization.Maulding ND, Kavanagh D, Zimmerman K, Coppola G, Carpenter TO, Jue NK, Braddock DT. Bone. 2021 Jan; 2020 Sep 24. PMID: 32980560.
• Phylogeny and chemistry of biological mineral transport.Schlesinger PH, Braddock DT, Larrouture QC, Ray EC, Riazanski V, Nelson DJ, Tourkova IL, Blair HC. Bone. 2020 Dec; 2020 Aug 26. PMID: 32858255.
• Unraveling the mechanism of recognition of the 3' splice site of the adenovirus major late promoter intron by the alternative splicing factor PUF60.Hsiao HT, Crichlow GV, Murphy JW, Folta-Stogniew EJ, Lolis EJ, Braddock DT. PLoS One. 2020; 2020 Nov 30. PMID: 33253191.
• Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles.Malik S, Lim J, Slack FJ, Braddock DT, Bahal R. J Control Release. 2020 Nov 10; 2020 Aug 21. PMID: 32835710.
• Genetic and pharmacologic modulation of cementogenesis via pyrophosphate regulators.Chu EY, Vo TD, Chavez MB, Nagasaki A, Mertz EL, Nociti FH, Aitken SF, Kavanagh D, Zimmerman K, Li X, Stabach PR, Braddock DT, Millán JL, Foster BL, Somerman MJ. Bone. 2020 Jul; 2020 Mar 26. PMID: 32224162.
• Paradoxical aortic stiffening and subsequent cardiac dysfunction in Hutchinson-Gilford progeria syndrome.Murtada SI, Kawamura Y, Caulk AW, Ahmadzadeh H, Mikush N, Zimmerman K, Kavanagh D, Weiss D, Latorre M, Zhuang ZW, Shadel GS, Braddock DT, Humphrey JD. J R Soc Interface. 2020 May; 2020 May 27. PMID: 32453981.
• Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations.Kotwal A, Ferrer A, Kumar R, Singh RJ, Murthy V, Schultz-Rogers L, Zimmermann M, Lanpher B, Zimmerman K, Stabach PR, Klee E, Braddock DT, Wermers RA. J Bone Miner Res. 2020 Apr; 2020 Jan 16. PMID: 31826312.
• Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency.Oheim R, Zimmerman K, Maulding ND, Stürznickel J, von Kroge S, Kavanagh D, Stabach PR, Kornak U, Tommasini SM, Horowitz MC, Amling M, Thompson D, Schinke T, Busse B, Carpenter TO, Braddock DT. J Bone Miner Res. 2020 Mar; 2019 Dec 5. PMID: 31805212.
• Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.Gordon CM, Cleveland RH, Baltrusaitis K, Massaro J, D'Agostino RB Sr, Liang MG, Snyder B, Walters M, Li X, Braddock DT, Kleinman ME, Kieran MW, Gordon LB. Bone. 2019 Aug; 2019 May 8. PMID: 31077852.
• Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice.Caballero D, Li Y, Fetene J, Ponsetto J, Chen A, Zhu C, Braddock DT, Bergwitz C. PLoS One. 2017; 2017 Jul 13. PMID: 28704395.
• In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery.Bahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM. Nat Commun. 2016 Oct 26; 2016 Oct 26. PMID: 27782131.
• ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy.Albright RA, Stabach P, Cao W, Kavanagh D, Mullen I, Braddock AA, Covo MS, Tehan M, Yang G, Cheng Z, Bouchard K, Yu ZX, Thorn S, Wang X, Folta-Stogniew EJ, Negrete A, Sinusas AJ, Shiloach J, Zubal G, Madri JA, De La Cruz EM, Braddock DT. Nat Commun. 2015 Dec 1; 2015 Dec 1. PMID: 26624227.
• MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ. Nature. 2015 Feb 5; 2014 Nov 17. PMID: 25409146.
• Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI. Nature. 2014 Jun 26; 2014 May 21. PMID: 24847880.
• Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke.Albright RA, Ornstein DL, Cao W, Chang WC, Robert D, Tehan M, Hoyer D, Liu L, Stabach P, Yang G, De La Cruz EM, Braddock DT. J Biol Chem. 2014 Feb 7; 2013 Dec 12. PMID: 24338010.
• Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy.Broer PN, Walker ME, Goldberg C, Buonocore S, Braddock DT, Lazova R, Narayan D, Ariyan S. Eur J Surg Oncol. 2013 Jul; 2013 Mar 22. PMID: 23522951.
• NPP4 is a procoagulant enzyme on the surface of vascular endothelium.Albright RA, Chang WC, Robert D, Ornstein DL, Cao W, Liu L, Redick ME, Young JI, De La Cruz EM, Braddock DT. Blood. 2012 Nov 22; 2012 Sep 20. PMID: 22995898.
• Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.Saunders LP, Cao W, Chang WC, Albright RA, Braddock DT, De La Cruz EM. J Biol Chem. 2011 Aug 26; 2011 Jun 30. PMID: 21719699.
• Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR.Hsiao HH, Nath A, Lin CY, Folta-Stogniew EJ, Rhoades E, Braddock DT. Biochemistry. 2010 Jun 8. PMID: 20420426.
• Autotaxin and lipid signaling pathways as anticancer targets.Braddock DT. Curr Opin Investig Drugs. 2010 Jun. PMID: 20496257.
• Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT. Mol Cancer Ther. 2008 Oct. PMID: 18852138.
• Histopathologic and molecular aspects of CD56+ natural killer/ T-cell lymphoma of the testis.Ornstein DL, Bifulco CB, Braddock DT, Howe JG. Int J Surg Pathol. 2008 Jul. PMID: 18573785.
• NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter.Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, Braddock DT, Muchmore SW, Comess KM, Fesik SW, Clore GM, Levens D, Hajduk PJ. J Med Chem. 2004 Sep 23. PMID: 15369388.
• Molecular basis of sequence-specific single-stranded DNA recognition by KH domains: solution structure of a complex between hnRNP K KH3 and single-stranded DNA.Braddock DT, Baber JL, Levens D, Clore GM. EMBO J. 2002 Jul 1. PMID: 12093748.
• Structure and dynamics of KH domains from FBP bound to single-stranded DNA.Braddock DT, Louis JM, Baber JL, Levens D, Clore GM. Nature. 2002 Feb 28. PMID: 11875576.
• Rapid identification of medium- to large-scale interdomain motion in modular proteins using dipolar couplings.Braddock DT, Cai M, Baber JL, Huang Y, Clore GM. J Am Chem Soc. 2001 Sep 5. PMID: 11525687.
• Biophysical characterization of gp41 aggregates suggests a model for the molecular mechanism of HIV-associated neurological damage and dementia.Caffrey M, Braddock DT, Louis JM, Abu-Asab MA, Kingma D, Liotta L, Tsokos M, Tresser N, Pannell LK, Watts N, Steven AC, Simon MN, Stahl SJ, Wingfield PT, Clore GM. J Biol Chem. 2000 Jun 30. PMID: 10747981.
• Treatment of autoimmune premature ovarian failure.Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Hum Reprod. 1999 Jul. PMID: 10402388.
• Structure-function relationships in side chain lactam cross-linked peptide models of a conserved N-terminal domain of apolipoprotein E.Benzinger TL, Braddock DT, Dominguez SR, Burkoth TS, Miller-Auer H, Subramanian RM, Fless GM, Jones DN, Lynn DG, Meredith SC. Biochemistry. 1998 Sep 22. PMID: 9748329.
• Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E.Braddock DT, Mercurius KO, Subramanian RM, Dominguez SR, Davies PF, Meredith SC. Biochemistry. 1996 Nov 5. PMID: 8909295.
• Structural and thermodynamic characterization of a bioactive peptide model of apolipoprotein E: side-chain lactam bridges to constrain the conformation.Luo P, Braddock DT, Subramanian RM, Meredith SC, Lynn DG. Biochemistry. 1994 Oct 18. PMID: 7918459.